Last edition
News about "Tumour microenvironment"
TAE Life Sciences’ latest research demonstrates the potential of next-generation BNCT to combine targeted radiation with immune activation for improved cancer treatment outcomes.
Tumour Microenvironment | 11/04/2026 | By News Bureau
Avacta Group doses first patient in AVA6103 trial, advances targeted cancer therapy platform
Phase I FOCUS-01 study to evaluate novel peptide-drug conjugate across four solid tumours following Euro 10 million fundraise and collaboration with Tempus AI.
Tumour Microenvironment | 11/04/2026 | By News Bureau | 169
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy